



## Treating Pediatric Patients With Generalized Myasthenia Gravis?

Consider **referring** your patient to an investigational study:

“An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis”

*The investigational study drug, efgartigimod PH20 SC, is not approved by the FDA for the treatment of pediatric patients with generalized myasthenia gravis as efficacy and safety have not been established.*



or visit [clinicaltrials.argenx.com/adaptjrsc](https://clinicaltrials.argenx.com/adaptjrsc) for more information